<DOC>
	<DOCNO>NCT01716793</DOCNO>
	<brief_summary>In protocol treatment AML use 1994 adult AML age 50 year , Spanish CETLAM group show complete remission rate 75 % use combination daunorubicin ( 60 mg/m2 , 3 day ) plus conventional dose cytarabine ( 100mg/m2/day continuous infusion 7 day ) etoposide ( 100mg/m2 IV/day 3 day ) . If idarubicin ( 10 mg/m2 , 3 day ) administer instead daunorubicin , complete remission ( CR ) rate adult 60 year 75 % . To improve proportion CRs decrease relapse rate appear 50 % patient , phase II AML-99 trial include intermediate dose-cytarabine induction risk-adapted post remission treatment base improvement prognostic characterization AML implementation novel transplantation technique .</brief_summary>
	<brief_title>Risk-adapted Therapy Adult Acute Myeloid Leukemia .</brief_title>
	<detailed_description>Induction chemotherapy : idarubicin ( 12mg/m2/day intravenous ) , intermediate-dose cytarabine ( 500mg/m2/12h , intravenous ) etoposide ( 100mg/m2/day , intravenous ) 3+7+3 schedule . This induction therapy repeat complete remission ( CR ) achieve first course treatment . Consolidation therapy : mitoxantrone ( 12mg/m2/day , intravenous , day 4 , 5 6 ) intermediate-dose cytarabine ( 500mg/m2/12h day 1 6 ) . Risk-stratification accord cytogenetics , course CR availability HLA-identical sibling : - Patients favorable cytogenetics group [ ( 8 ; 21 ) , inv ( 16 ) ( 16 ; 16 ) ] treat high-dose cytarabine ( 3g/m2/12h , intravenous , day 1 , 3 5 ) . - Patients intermediate cytogenetics group ( normal karyotype single course achieve CR ) receive autologous peripheral blood stem cell ( PBSC ) transplant , regardless HLA-identical sibling . - The remain patient consider high-risk group treat autologous allogeneic PBSC transplantation depend availability sibling donor . In allotransplants , CD34+ cell selection hematopoietic cell perform .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patients newly diagnose AML , classify FAB criterion Age superior 60 year Verbal inform consent chemotherapy write mobilization stem cell transplantation Patients treat previously AML chemotherapy different hydroxyurea Acute promyelocytic leukemia ( M3 ) Chronic myeloid leukemia blastic crisis Leukemias appear myeloproliferative process Leukemias survive myelodysplastic syndrome 6 month evolution Presence neoplastic disease activity Secondary AML appear cured malignancy ( instance Hodgkin disease ) still expose alkylant agent radiation Renal hepatic abnormal function creatinine value and/or bilirubin two time higher normal threshold , except alteration could attribute leukemia Patients fraction ejection low ( inferior 40 % ) , symptomatic cardiac insufficiency Patients grave concomitant neurological psychiatric disease Positivity HIV ( donor and/or receptor )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Primary AML</keyword>
	<keyword>Risk-adapted treatment</keyword>
	<keyword>Hematopoietic transplantation</keyword>
	<keyword>CD34+ cell selection</keyword>
</DOC>